CoChat
Sign Up
Cited by 154Liver Disease and TransplantationLiver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial

Open access
Pose, Elisa, Napoleone, Laura, Amin, Ahmed, Campion, Daniela, Jimenez, César, Piano, Salvatore, Roux, Olivier, Uschner, Frank Erhard +22 more·2020·The Lancet Gastroenterology & Hepatology
DOI 10.1016/s2468-1253(19)30320-6
Open this paper in CoChat — free account

Abstract

Background Statins have beneficial effects on intrahepatic circulation and decrease portal hypertension and rifaximin modulates the gut microbiome and might prevent bacterial translocation in patients with cirrhosis. Therefore, this drug combination might be of therapeutic benefit in patients with decompensated cirrhosis. However, there is concern regarding the safety of statins in patients with decompensated cirrhosis. We assessed the safety of two different doses of simvastatin, in combination with rifaximin, in patients with decompensated cirrhosis.Methods We did a double-blind, randomised, placebo-controlled, phase 2 trial in patients with decompensated cirrhosis and moderate-to-severe liver failure from nine university hospitals in six European countries (Italy, France, Holland, Germany, the UK, and Spain). Patients older than 18 years with Child-Pugh class B or C disease were eligible. We randomly assigned patients (1:1:1) to receive either simvastatin 40 mg/day plus rifaximin 1200 mg/day, simvastatin 20 mg/day plus rifaximin 1200 mg/day, or placebo of both medications for 12 weeks. Randomisation was stratified according to Child-Pugh class (B vs C) and restricted using blocks of multiples of three. The primary endpoint was development of liver or muscle toxicity, as defined by changes in liver aminotransferases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]), alkaline phosphastase, and creatine kinase. The study is registered with the European Union Clinical Trials Register, 2016-004499-23, and with ClinicalTrials.gov, NCT03150459.Findings The study recruitment period was between July 28, 2017, and Jan 2, 2018. Follow-up finished on March 12, 2018. 50 patients were randomly assigned to simvastatin 40 mg/day plus rifaximin 1200 mg/day (n=18), simvastatin 20 mg/day plus rifaximin 1200 mg/day (n=16), or placebo of both medications (n=16). Six patients (two from each group) were excluded. Therefore, the full analysis set included 44 patients (16 in the simvastatin 40 mg/day plus rifaximin 1200 mg/day group, 14 in the simvastatin 20 mg/day plus rifaximin mg/day group, and 14 in the placebo group). After a safety analyses when the first ten patients completed treatment, treatment was stopped prematurely in the simvastatin 40 mg/day plus rifaximin group due to recommendations by the data safety monitoring board. Patients in the simvastatin 40 mg/day plus rifaximin group showed a significant increase in AST and ALT compared with the placebo group (mean differences between the groups at the end of treatment for AST 130 IU/L [95% CI 54 to 205; p=0·0009] and for ALT 61 IU/L [22 to 100; p=0·0025]. We observed no significant differences at 12 weeks in AST and ALT between the simvastatin 20 mg/day plus rifaximin and placebo group (for AST -14 IU/L [-91 to 64; p=0·728] and for ALT -8 IU/L [-49 to 33; p=0·698]). We observed no significant differences in alkaline phosphatase between the the simvastatin 40 mg/day plus rifaximin or the simvastatin 20 mg/day plus rifaximin groups compared with placebo. Patients in the simvastatin 40 mg/day plus rifaximin group showed an increase in creatine kinase at the end of treatment compared with patients in the placebo group (1009 IU/L [208 to 1809]; p=0·014). We observed no significant changes in creatine kinase in the simvastatin 20 mg/day plus rifaximin group (4·2 IU/L [-804 to 813]; p=0·992). Three (19%) patients in the simvastatin 40 mg/day group developed liver and muscle toxicity consistent with rhabdomyolysis. The number of patients who stopped treatment because of adverse events was significantly higher in the simvastatin 40 mg/day plus rifaximin group (nine [56%] of 16 patients) compared with the other two groups (two [14%] of 14 for both groups; p=0·017). There were no serious unexpected adverse reactions reported during the study.Interpretation Treatment with simvastatin 40 mg/day plus rifaximin in patients with decompensated cirrhosis was associated with a significant increase in adverse events requiring treatment withdrawal, particularly rhabdomyolysis, compared with simvastatin 20 mg/day plus rifaximin. We recommend simvastatin 20 mg/day as the dose to be used in studies investigating the role of statins in patients with decompensated cirrhosis.Funding Horizon 20/20 European programme.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2468-1253(19)30320-6

Cites

28 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a multicentre European clinical trial in individuals with Child-Pugh class B or C cirrhosis, 19% of those receiving simvastatin 40 mg daily developed liver toxicity and rhabdomyolysis.

    “In a multicentre European clinical trial in individuals with Child-Pugh class B or C cirrhosis, 19% of those receiving simvastatin 40 mg daily developed liver toxicity and rhabdomyolysis. 472”

    From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [472]

    The Discussion reports that 3 of 16 patients (19%) receiving simvastatin 40 mg/day developed muscle toxicity associated with liver toxicity, consistent with rhabdomyolysis. However, they received rifaximin alongside simvastatin, which the claim omits. The Discussion also cautions that the liver origin of the elevated enzymes could not be established convincingly. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • A recent study has reported increased adverse events rates in patients with decompensated cirrhosis under 40 mg/day of simvastatin (combined with rifaximin) therapy, compared to 20 mg/day.

    “A recent study has however reported increased adverse events rates in patients with decompensated cirrhosis under 40 mg/day of simvastatin (combined with rifaximin) therapy, compared to 20 mg/day [96].”

    From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [96]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Corr. Guideline on Data Monitoring Committees. URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_ content_001225.jsp&mid=WC0b01ac05807d91a4 2016.

Cited by

Sorted by citations

Related

Authors
Pose, E., Napoleone, L., Amin, A., Campion, D., Jimenez, C., Piano, S., Roux, O., Uschner, F. E., de Wit, K., Zaccherini, G., Alessandria, C., Angeli, P., Bernardi, M., Beuers, U., Caraceni, P., Durand, F., Mookerjee, R. P., Trebicka, J., Vargas, V., Andrade, R. J., Carol, M., Pich, J., Ferrero, J., Domenech, G., Llopis, M., Torres, F., Kamath, P. S., Abraldes, J. G., Solà, E., & Ginès, P.
Affiliations
  • Hospital Clínic de Barcelona (ES)
  • University College London (GB)
  • Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
  • University of Padua (IT)
  • Hôpital Beaujon (FR)
  • Goethe University Frankfurt (DE)
  • University of Bologna (IT)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
  • European Clinical Research Infrastructure Network (FR)
  • Mayo Clinic (US)
Corresponding author
Ginès, Pere
ORCID
Venue
The Lancet Gastroenterology & Hepatology
Publisher
Elsevier BV
Published
2020-01
Volume
5
Issue
1
Pages
31-41
ISSN
  • 2468-1156 (ISSN-L)
  • 2468-1253
DOI
10.1016/s2468-1253(19)30320-6
OpenAlex
W2979606780
Cited by
154
References
28
Citations by year
2026: 21 · 2025: 21 · 2024: 30 · 2023: 23 · 2022: 17 · 2021: 28 · 2020: 13 · 2013: 1
FWCI
9.24
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet. Gastroenterology & hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by-nc-nd)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
  • UCL Discovery (University College London) (submittedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
Instituto de Salud Carlos III
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
simvastatin, rifaximin, decompensated cirrhosis, liver failure, drug safety, statin dose comparison, liver aminotransferases, creatine kinase, muscle toxicity, bacterial translocation, gut microbiota, portal hypertension, Child-Pugh score, adverse events, drug-drug interactions
MeSH terms
Rifaximin, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Follow-Up Studies, Gastrointestinal Agents, Humans, Hypertension, Portal, Liver Cirrhosis, Treatment Outcome, Portal Pressure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review